May 15, 2020 / 11:20 AM / 16 days ago

BRIEF-Can-Fite Announces Pre-Ind Submission To FDA For Piclidenoson

May 15 (Reuters) - Can Fite Biopharma Ltd:

* CAN-FITE ANNOUNCES PRE-IND SUBMISSION TO U.S. FDA FOR PICLIDENOSON IN THE TREATMENT OF COVID-19 INFECTED PATIENTS WITH MODERATE-TO-SEVERE SYMPTOMS

* CAN FITE BIOPHARMA LTD - THROUGH PRE-IND, CO ANTICIPATES RECEIVING FDA’S ADVICE AND GUIDANCE ON ITS PLANNED CLINICAL STUDY PROTOCOL FOR PICLIDENOSON

* CAN FITE BIOPHARMA - MAY SUBMIT IND APPLICATION FOR PICLIDENOSON TO BE EVALUATED AS POTENTIAL ADDITION TO CURRENT STANDARD OF CARE COVID-19 TREATMENT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below